Daniel Keizman
Overview
Explore the profile of Daniel Keizman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
764
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grunwald V, McKay R, Buchler T, Eto M, Park S, Takagi T, et al.
Int J Cancer
. 2024 Dec;
156(7):1326-1335.
PMID: 39739622
Lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib in treatment of advanced renal cell carcinoma (aRCC) in the phase 3 CLEAR study. We report results of an exploratory post hoc...
2.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...
3.
Keizman D, Frenkel M, Peer A, Rosenbaum E, Sarid D, Leibovitch I, et al.
Nutrients
. 2023 Aug;
15(16).
PMID: 37630724
The optimal therapy for patients with non-metastatic biochemically relapsed prostate cancer (BRPC-M0) after local therapy is elusive. Thus, the evaluation of new non-toxic compounds in BRPC-M0 patients is warranted. PectaSol-Modified...
4.
Rouvinov K, Levanon E, Peer A, Sarfaty M, Sarid D, Neiman V, et al.
Front Oncol
. 2023 Jun;
13:1151701.
PMID: 37293597
Background: Erdafitinib, a fibroblast growth factor receptor (FGFR) inhibitor is a standard post chemotherapy advanced treatment line for metastatic urothelial carcinoma harboring FGFR2/3 genomic alterations. It was approved based on...
5.
Kesler M, Cohen D, Levine C, Sarid D, Keizman D, Yossepowitch O, et al.
J Nucl Med
. 2023 Apr;
64(7):1030-1035.
PMID: 37116912
Although prostate-specific membrane antigen (PSMA) PET/CT has been shown valuable for staging biopsy-proven [B(+)] high-risk prostate cancer, elderly patients are occasionally referred for PSMA PET/CT without a preimaging confirming biopsy...
6.
Dekalo S, Kuten J, Campbell J, Mintz I, Bar-Yosef Y, Keizman D, et al.
Can Urol Assoc J
. 2022 Mar;
16(7):E381-E385.
PMID: 35230941
Introduction: Current guidelines do not support the use of pretreatment imaging in patients with favorable intermediate-risk prostate cancer. Ga-prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is more accurate...
7.
Keizman D, Frenkel M, Peer A, Kushnir I, Rosenbaum E, Sarid D, et al.
Nutrients
. 2021 Dec;
13(12).
PMID: 34959847
Optimal therapy of biochemically relapsed prostate cancer (BRPC) after local treatment is elusive. An established modified citrus pectin (PectaSol, P-MCP), a dietary polysaccharide, is an established antagonist of galectin-3, a...
8.
Kesler M, Kerzhner K, Druckmann I, Kuten J, Levine C, Sarid D, et al.
Eur J Nucl Med Mol Imaging
. 2021 Dec;
49(6):2077-2085.
PMID: 34957528
Purpose: The aim of the study was to elaborate the incidence and type of skeletal involvement in a large cohort of patients with newly diagnosed prostate cancer (PCa) referred for...
9.
Dekalo S, Kuten J, Mintz I, Fahoum I, Gitstein G, Keizman D, et al.
Prostate Cancer Prostatic Dis
. 2021 Apr;
24(3):910-916.
PMID: 33790418
Background: High-risk prostate cancer is associated with adverse pathology and unfavorable outcomes after radical prostatectomy. Ga-PSMA PET/CT is more accurate than conventional imaging for preoperative staging. We aimed to evaluate...
10.
Sartor O, Heinrich D, Mariados N, Mendez Vidal M, Keizman D, Thellenberg Karlsson C, et al.
Prostate
. 2019 Aug;
79(14):1683-1691.
PMID: 31442327
Background: Radium-223 dichloride (radium-223) is approved for patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no visceral disease using a dosing regimen of 6 injections (55 kBq/kg intravenously;...